| Medical and Health Sciences | Lifetime | 105 | GB 13 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 4 | GB 2 | 100.00 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 2 | GB 1 | 99.98 |
| Epidemiology | Lifetime | 322 | GB 25 | 99.60 |
| Public, Environmental and Occupational Health | Lifetime | 336 | GB 47 | 99.52 |
| General Health Professions | Lifetime | 591 | GB 96 | 99.32 |
| Medical Physiology | Lifetime | 543 | GB 60 | 99.08 |
| Cardiology and Cardiovascular Medicine | Lifetime | 706 | GB 52 | 98.67 |
| Pharmacy | Lifetime | 216 | GB 20 | 97.36 |
| Infectious Diseases | Lifetime | 541 | GB 45 | 97.86 |
| Geriatrics and Gerontology | Lifetime | 230 | GB 24 | 94.41 |
| Family Practice | Lifetime | 103 | GB 9 | 93.99 |
| Clinical Neurology | Lifetime | 986 | GB 98 | 93.40 |
| Health | Lifetime | 946 | GB 122 | 91.75 |
| Obstetrics and Gynecology | Lifetime | 803 | GB 108 | 88.48 |
| Nephrology | Lifetime | 897 | GB 59 | 84.45 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 2 | GB 1 | 99.98 |
| Epidemiology | 2021-2025 | 43 | GB 5 | 99.78 |
| Infectious Diseases | 2021-2025 | 29 | GB 2 | 99.60 |
| General Health Professions | 2021-2025 | 72 | GB 9 | 99.51 |
| Clinical Neurology | 2021-2025 | 36 | GB 9 | 99.25 |
| Medical Physiology | 2021-2025 | 75 | GB 12 | 99.01 |
| Public, Environmental and Occupational Health | 2021-2025 | 151 | GB 9 | 98.70 |
| Oncology | 2021-2025 | 133 | GB 6 | 99.11 |
| Health | 2021-2025 | 95 | GB 20 | 97.67 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 250 | GB 16 | 98.02 |
| Surgery | 2021-2025 | 390 | GB 25 | 97.09 |
| Clinical Psychology | 2021-2025 | 556 | GB 67 | 94.60 |
| Obstetrics and Gynecology | 2021-2025 | 191 | GB 27 | 93.85 |
| Genetics | 2021-2025 | 346 | GB 44 | 90.58 |
| Geriatrics and Gerontology | 2021-2025 | 100 | GB 11 | 89.94 |
| Family Practice | 2021-2025 | 41 | GB 5 | 84.24 |
| Nephrology | 2021-2025 | 229 | GB 12 | 86.42 |
| Diabetes Management and Research | Lifetime | 1 | GB 1 | 99.96 |
| Chronic Disease Management Strategies | Lifetime | 1 | GB 1 | 99.95 |
| COVID-19 Clinical Research Studies | Lifetime | 4 | GB 1 | 99.95 |
| COVID-19 and healthcare impacts | Lifetime | 2 | GB 1 | 99.95 |
| Diabetes Management and Education | Lifetime | 1 | GB 1 | 99.95 |
| Long-Term Effects of COVID-19 | Lifetime | 3 | GB 1 | 99.86 |
| Diabetes Treatment and Management | Lifetime | 5 | GB 1 | 99.95 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 22 | GB 3 | 99.88 |
| Metabolism, Diabetes, and Cancer | Lifetime | 36 | GB 2 | 99.78 |
| Diabetes and associated disorders | Lifetime | 49 | GB 6 | 99.59 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 18 | GB 4 | 99.50 |
| COVID-19 and Mental Health | Lifetime | 64 | GB 15 | 99.15 |
| Clinical practice guidelines implementation | Lifetime | 42 | GB 6 | 99.26 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 194 | GB 32 | 99.36 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 26 | GB 9 | 99.23 |
| Pharmacology and Obesity Treatment | Lifetime | 49 | GB 5 | 99.21 |
| Medication Adherence and Compliance | Lifetime | 45 | GB 3 | 98.89 |
| Physical Activity and Health | Lifetime | 88 | GB 12 | 99.26 |
| Primary Care and Health Outcomes | Lifetime | 139 | GB 26 | 98.92 |
| Diet and metabolism studies | Lifetime | 464 | GB 49 | 99.12 |
| Obesity and Health Practices | Lifetime | 76 | GB 11 | 98.90 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 153 | GB 18 | 98.34 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 487 | GB 40 | 98.38 |
| Mobile Health and mHealth Applications | Lifetime | 132 | GB 19 | 98.34 |
| Pancreatic function and diabetes | Lifetime | 579 | GB 57 | 98.36 |
| Bariatric Surgery and Outcomes | Lifetime | 160 | GB 11 | 97.95 |
| Obesity, Physical Activity, Diet | Lifetime | 687 | GB 99 | 98.44 |
| Cardiac Health and Mental Health | Lifetime | 302 | GB 25 | 97.85 |
| Blood Pressure and Hypertension Studies | Lifetime | 761 | GB 69 | 97.91 |
| Heart Failure Treatment and Management | Lifetime | 756 | GB 52 | 97.42 |
| Lipoproteins and Cardiovascular Health | Lifetime | 709 | GB 71 | 97.21 |
| Cardiovascular Health and Risk Factors | Lifetime | 277 | GB 20 | 96.41 |
| Vaccine Coverage and Hesitancy | Lifetime | 680 | GB 59 | 96.08 |
| Chronic Kidney Disease and Diabetes | Lifetime | 799 | GB 38 | 95.85 |
| Gestational Diabetes Research and Management | Lifetime | 830 | GB 90 | 95.57 |
| Medical Coding and Health Information | Lifetime | 98 | GB 15 | 92.70 |
| Dietary Effects on Health | Lifetime | 502 | GB 56 | 92.12 |
| Ethics in Clinical Research | Lifetime | 834 | GB 109 | 90.49 |
| Potassium and Related Disorders | Lifetime | 735 | GB 45 | 87.90 |
| Healthcare Systems and Challenges | Lifetime | 293 | GB 129 | 81.23 |
| Romani and Gypsy Studies | Lifetime | 774 | GB 131 | 49.87 |
| COVID-19 Clinical Research Studies | 2021-2025 | 1 | GB 1 | 99.98 |
| COVID-19 and healthcare impacts | 2021-2025 | 1 | GB 1 | 99.97 |
| Diabetes Management and Research | 2021-2025 | 1 | GB 1 | 99.97 |
| Chronic Disease Management Strategies | 2021-2025 | 1 | GB 1 | 99.98 |
| Diabetes Management and Education | 2021-2025 | 1 | GB 1 | 99.94 |
| Long-Term Effects of COVID-19 | 2021-2025 | 6 | GB 1 | 99.86 |
| Diabetes Treatment and Management | 2021-2025 | 11 | GB 3 | 99.92 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 12 | GB 2 | 99.65 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 13 | GB 2 | 99.50 |
| COVID-19 and Mental Health | 2021-2025 | 60 | GB 11 | 99.03 |
| Diabetes and associated disorders | 2021-2025 | 19 | GB 2 | 99.05 |
| Diet and metabolism studies | 2021-2025 | 51 | GB 3 | 99.16 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 6 | GB 1 | 98.87 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 92 | GB 18 | 98.58 |
| Physical Activity and Health | 2021-2025 | 60 | GB 11 | 98.23 |
| Mobile Health and mHealth Applications | 2021-2025 | 67 | GB 9 | 97.28 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 507 | GB 45 | 97.93 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 206 | GB 21 | 96.67 |
| Pharmacology and Obesity Treatment | 2021-2025 | 28 | GB 4 | 97.35 |
| Obesity and Health Practices | 2021-2025 | 46 | GB 8 | 95.88 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 19 | GB 2 | 94.79 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 132 | GB 11 | 96.45 |
| Primary Care and Health Outcomes | 2021-2025 | 128 | GB 12 | 94.58 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 285 | GB 26 | 95.45 |
| Gestational Diabetes Research and Management | 2021-2025 | 278 | GB 27 | 92.92 |
| Heart Failure Treatment and Management | 2021-2025 | 439 | GB 41 | 94.71 |
| Bariatric Surgery and Outcomes | 2021-2025 | 219 | GB 15 | 93.82 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 264 | GB 30 | 92.99 |
| Ethics in Clinical Research | 2021-2025 | 154 | GB 16 | 91.39 |
| Climate Change and Health Impacts | 2021-2025 | 585 | GB 42 | 91.59 |
| Healthcare cost, quality, practices | 2021-2025 | 170 | GB 25 | 90.25 |
| Medication Adherence and Compliance | 2021-2025 | 162 | GB 10 | 89.85 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 704 | GB 62 | 90.45 |
| Clinical practice guidelines implementation | 2021-2025 | 178 | GB 18 | 87.35 |
| Potassium and Related Disorders | 2021-2025 | 105 | GB 6 | 91.31 |
| Frailty in Older Adults | 2021-2025 | 706 | GB 68 | 90.14 |
| Cardiac Health and Mental Health | 2021-2025 | 595 | GB 46 | 86.34 |
| Migration, Health and Trauma | 2021-2025 | 807 | GB 73 | 84.58 |
| Healthcare Systems and Challenges | 2021-2025 | 34 | GB 8 | 84.04 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 618 | GB 81 | 80.88 |
| Global Health Care Issues | 2021-2025 | 813 | GB 95 | 79.40 |
| Diabetic Foot Ulcer Assessment and Management | 2021-2025 | 650 | GB 55 | 82.91 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 619 | GB 25 | 81.88 |
| Statistical Methods in Clinical Trials | 2021-2025 | 458 | GB 68 | 79.71 |
| Medical Coding and Health Information | 2021-2025 | 107 | GB 25 | 64.33 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 656 | GB 60 | 62.37 |
| Romani and Gypsy Studies | 2021-2025 | 64 | GB 6 | 60.67 |
| Healthcare Systems and Technology | 2021-2025 | 718 | GB 92 | 57.55 |
| Infectious Encephalopathies and Encephalitis | 2021-2025 | 652 | GB 27 | 51.33 |